Gilde Healthcare anchors $103.5 million public offering by Affimed - Gilde Healthcare

Gilde Healthcare anchors $103.5 million public offering by Affimed

April 21, 2022
Utrecht (the Netherlands)

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed.

“We are excited to team up with the excellent team at Affimed, who are front-runners in engaging the innate immune system to fight some of the most difficult-to-treat cancers,” said Joep Muijrers, General Partner at Gilde Healthcare and responsible for Gilde’s public investment franchise. “We are proud to add Affimed to our expanding portfolio, and look forward to closely working with them in the years to come”.

Pieter van der Meer, Managing Partner of Gilde Healthcare commented “We followed Affimed for many years and are convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring the public offering we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.”

The full text of the announcement from Affimed can be found here:
Affimed announces closing of public offering of common shares and full exercise of underwriters’ option to purchase additional shares – Affimed.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023